Long-term survival following upgrade compared with de novo cardiac resynchronization therapy implantation: a single-centre, high-volume experience
| Autor: | W R Schwertner, Boglárka Veres, László Gellér, Levente Molnár, Annamaria Kosztin, Márton Tokodi, István Osztheimer, Roland Papp, E.D Merkel, A Behon, Béla Merkely, Luca Kuthi, Endre Zima, Ákos Király, Attila Kovács |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Cardiac resynchronization therapy De novo CRT Ventricular Function Left Upgrade Clinical Research Pacing and Cardiac Resynchronization Therapy Physiology (medical) Internal medicine medicine Risk of mortality Humans AcademicSubjects/MED00200 Cardiac Resynchronization Therapy Devices Retrospective Studies Heart Failure Heart transplantation Ejection fraction Surrogate endpoint business.industry Hazard ratio Stroke Volume All-cause mortality medicine.disease Comorbidity Defibrillators Implantable Treatment Outcome Ventricular assist device Cardiology Female Cardiology and Cardiovascular Medicine business Complication |
| Zdroj: | Europace |
| ISSN: | 1532-2092 1099-5129 |
| DOI: | 10.1093/europace/euab059 |
| Popis: | Aims Patients with a pacemaker or implantable cardioverter-defibrillator are often considered for cardiac resynchronization therapy (CRT). However, limited comprehensive data are available regarding their long-term outcomes. Methods and results Our retrospective registry included 2524 patients [1977 (78%) de novo, 547 (22%) upgrade patients] with mild to severe symptoms, left ventricular ejection fraction ≤35%, and QRS ≥ 130ms. The primary outcome was the composite of all-cause mortality, heart transplantation (HTX), or left ventricular assist device (LVAD) implantation; secondary endpoints were death from any cause and post-procedural complications. In our cohort, upgrade patients were older [71 (65–77) vs. 67 (59–73) years; P Conclusion In our retrospective analysis, upgrade patients had a higher risk of all-cause mortality than de novo patients, which might be attributable to their more significant comorbidity burden. The occurrence of lead dysfunction and pocket infections was more frequent in the upgrade group. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|